REAL WORLD EVIDENCE NEEDS IN ONCOLOGY:
Gastroesophageal Cancer
White Paper based on new trial results from ESMO Congress, 20-24 October 2023, Madrid.
The varying nature of gastroesophageal cancer, spanning from localized, indolent tumors to aggressive, metastatic forms, coupled with the emergence of resistance to established treatments, emphasizes the urgent requirement for ongoing research and clinical trials aimed at improving patient outcomes.
OXON’s assessment of the research findings presented at ESMO 2023 and their potential implications for existing clinical protocols and practices offers a thorough insight, assisting in pinpointing the real-world evidence (RWE) deficiencies in the management of gastroesophageal cancer.